If you know you carry a hereditary mutation (such as Lynch syndrome, or others), you already understand the importance of vigilance. Genetic predisposition highlights possibility but it does not provide information about what’s happening in your body right now.
The miRoncol Real-time Multi-Cancer Early Risk Assessment adds a real-time biological layer to your preventive strategy, giving you and your physician more context for monitoring and follow-up.
The miRoncol test evaluates microRNA signatures linked to common solid tumours, providing:
This test is not a replacement for genetic counselling or physician-recommended surveillance. Instead, it provides additional real-time biological context that may help guide discussions and follow-up planning.
For patients with known genetic risk factors, knowledge is power but so is current biological insight. miRoncol helps bridge the gap by showing what’s happening in your body today.